 | Vol. 11.27 – 13 July, 2022 |
| |
|
|
| Investigators demonstrated that lower expression of MAN1A1 in glioma stem cells resulted in the formation of high-mannose type N-glycan on CD133. [Advanced Science] |
|  |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists reported that little characterized cysteine-rich protein 1 (CRIP1) was upregulated in hepatocellular carcinoma and associated with poor prognosis. [EMBO Journal] |
|
|
|
| Investigators found that PFK158 treatment and PFKFB3 knockdown enhanced the ABCG2-interacting drugs doxorubicin, etoposide, and 5-fluorouracil in reducing cell viability under conditions of enriched CSCs. [Oncogene] |
|
|
|
| Researchers built a 3D in vitro model system of bone marrow (BM) organoids that recapitulated several structural and cellular components of native BM. [APL Bioengineering] |
|
|
|
| To determine the regulatory action of NOTCH1-cMYC signaling in CSC maintenance, scientists evaluated the effect of a selective NOTCH1 inhibitor, crenigacestat, on CSC capacities in anaplastic thyroid cancer. [Thyroid] |
|
|
|
| The authors investigated the photothermal effect of gold nanorods on human neuroblastoma CD133+ CSCs via autophagic cell death. [Scientific Reports] |
|
|
|
| Scientists prospectively collected circulating tumor cell data from patients with operable non-metastatic esophageal cancer from April 2009 to November 2016 enrolled in their QUINTETT esophageal cancer randomized trial. [BMC Cancer] |
|
|
|
| The authors analyzed 29 stem cell collections of 19 adult patients at a median age of 27 years mobilized after vincristine, ifosfamide, doxorubicine, and etoposide, dactinomycin, and ifosfamide chemotherapy. [Transfusion] |
|
|
|
| Scientists explored whether casticin suppressed stemness in cancer stem-like cells obtained from human cervical cancer and the underlying mechanism. [Chinese Journal of Integrative Medicine] |
|
|
|
|
| The selective persistence of rare leukemic stem cells following therapy-induced remission implies unique resistance mechanisms of leukemic stem cells towards conventional therapeutic strategies and that leukemic stem cells represent the cellular origin of relapse. [Journal of Internal Medicine] |
|
|
|
|
| The Medical Research Council, Cancer Research UK, and Wellcome have announced £1 billion of funding for the Francis Crick Institute helping secure the future of the UK as a scientific powerhouse. [The Francis Crick Institute] |
|
|
|
|
| September 12 – 14, 2022 Liverpool, England, United Kingdom |
|
|
|
|
|
| The Chinese University of Hong Kong – Hong Kong, China |
|
|
|
| Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| Université catholique de Louvain – Brussels, Belgium |
|
|
|
| Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| Boehringer Ingelheim – Vienna, Austria |
|
|
|
|